Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine whether high-dose intravenous immune globulin (IVIG) is more
effective than placebo in restoring neurologic function (muscle strength) in patients with
multiple sclerosis.
II. Determine the time to recovery following IVIG.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)